Envista Holdings Corporation
NVST
$24.24
-0.21%
Envista Holdings Corporation is a dental products company that develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals, operating within the Medical Equipment & Services industry. The company is a significant player in the dental market, distinct for its dual-segment structure focused on high-margin specialty products like dental implant systems and orthodontic solutions, alongside a broader equipment and consumables business. The current investor narrative is driven by a strong recovery in financial performance, as evidenced by a significant year-over-year revenue surge in its latest quarter, alongside a strategic focus on its higher-growth Specialty Products & Technologies segment, which now generates the majority of its revenue.…
NVST
Envista Holdings Corporation
$24.24
Investment Opinion: Should I buy NVST Today?
Rating & Thesis: Hold. NVST is a compelling turnaround story with strong operational momentum, but its recent massive rally and high forward earnings expectations leave limited near-term upside and elevate risk, warranting a neutral stance pending further evidence of sustained execution. This aligns with the analyst consensus, which leans neutral.
Supporting Evidence: The Hold rating is supported by four key data points. First, the forward P/E of 17.2x is reasonable but fully prices in the projected EPS surge to $1.89. Second, while revenue growth is robust at 14.96% YoY, it must be sustained to justify the multiple. Third, profitability has recovered dramatically, with Q4 2025 net income of $32.9M. Fourth, the stock trades near its 52-week high after a 67.71% annual gain, suggesting much of the positive news is already reflected in the price.
Risks & Conditions: The two biggest risks are a growth deceleration below 10% YoY and a failure to hit the $1.89 EPS target, either of which would compress the forward P/E multiple. This Hold would upgrade to a Buy if the stock pulls back to the low-$20s (offering a better entry point) while growth metrics remain intact, or if Q1 2026 earnings demonstrate an acceleration in growth. It would downgrade to a Sell if revenue growth decelerates sharply or if operating margins show signs of contraction. The stock is currently fairly valued relative to its forward earnings potential but overextended on a technical basis following its powerful rally.
Sign up to view all
NVST 12-Month Price Forecast
The investment case for NVST is balanced. The operational turnaround is impressive, with strong revenue growth and a return to profitability. However, the stock's powerful rally has likely front-run much of the good news, leaving limited margin for error. The forward P/E of 17.2x is fair but not cheap, requiring flawless execution. The neutral stance reflects this equilibrium between improving fundamentals and elevated expectations. We would upgrade to bullish on a pullback to the low-$20s that improves the risk/reward profile, or on evidence of accelerating growth. A downgrade to bearish would be triggered by a material slowdown in revenue growth or a breakdown below key technical support at $25.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Envista Holdings Corporation's 12-month outlook, with a consensus price target around $31.51 and implied upside of +30.0% versus the current price.
Average Target
$31.51
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$19 - $32
Analyst target range
Analyst coverage for NVST is limited, with only 4 analysts providing estimates, which is typical for a mid-cap company and can lead to higher volatility and less efficient price discovery. The consensus leans neutral, as evidenced by recent institutional ratings where firms like Mizuho, Piper Sandler, JP Morgan, and UBS have 'Neutral' or 'Equal Weight' stances, while Stifel and Barclays maintain 'Buy' or 'Overweight' ratings. The average estimated EPS for the coming period is $1.89, with a tight range from $1.87 to $1.92, indicating strong agreement on the near-term earnings trajectory. The target price range is not explicitly provided in the data, but the tight EPS estimate range suggests analysts have a consolidated view on fundamentals. The high end of the EPS range ($1.92) likely assumes successful execution on margin expansion and segment growth, while the low end ($1.87) may factor in potential macroeconomic or competitive pressures. The lack of a wide dispersion in estimates points to a higher degree of conviction in the near-term financial model, though the limited number of covering analysts means this view is not broad-based.
Bulls vs Bears: NVST Investment Factors
The bull case for NVST, anchored in a dramatic financial turnaround, strong revenue growth, and reasonable forward valuation, currently holds stronger evidence than the bear case, which focuses on elevated trailing multiples and post-rally exhaustion. The most critical tension in the investment debate is whether the company can sustain its recent 14.96% revenue growth and margin expansion to justify the forward P/E of 17.2x and achieve the analyst-projected EPS of $1.89. If execution meets these high expectations, the stock could break above its 52-week high; if growth decelerates, the valuation multiple is at risk of significant compression.
Bullish
- Strong Revenue Growth & Momentum: Q4 2025 revenue grew 14.96% YoY to $750.6M, accelerating from $616.9M in Q1 2025. This demonstrates robust demand and successful execution, particularly in the high-margin Specialty Products segment, which now generates the majority of revenue.
- Dramatic Profitability Recovery: The company swung from a net loss of -$303M in Q3 2025 to a net income of $32.9M in Q4 2025. The operating margin recovered to 10.10% in Q4 2025 from a crisis-level -182.17% in Q2 2024, signaling a successful turnaround.
- Attractive Forward Valuation: The forward P/E of 17.2x, based on analyst EPS estimates of $1.89, is reasonable for a healthcare equipment company and represents a massive discount to the trailing P/E of 77.6x. This suggests the market has priced in the earnings recovery, leaving room for upside if execution continues.
- Robust Cash Generation & Balance Sheet: The company generated $230.4M in TTM free cash flow and has a strong current ratio of 2.38. This provides ample internal funding for growth initiatives and share repurchases, reducing financial risk.
Bearish
- Elevated Trailing P/E & High Expectations: The trailing P/E of 77.6x is extremely high, indicating the stock's recent price surge has far outpaced current earnings. This leaves the stock vulnerable to multiple compression if future earnings growth fails to meet the high expectations embedded in the forward P/E of 17.2x.
- Significant Post-Rally Consolidation: The stock's 1-month return of 2.52% lags the S&P 500's 8.7% gain, resulting in a negative relative strength of -6.18. This deceleration suggests the powerful rally may be exhausting, and the stock is digesting its gains near the 52-week high of $30.42.
- Modest Return Metrics & Recent Volatility: Return on Equity (ROE) is a modest 1.51%, reflecting the company's recent journey back to profitability. The stock has also demonstrated volatility with a maximum drawdown of -19.83% over the past year, indicating significant price swings despite a market-aligned beta of 0.985.
- Limited Analyst Coverage & Neutral Sentiment: Only 4 analysts cover the stock, which can lead to less efficient price discovery and higher volatility. The consensus sentiment is neutral, with several major firms (Mizuho, Piper Sandler, JP Morgan, UBS) rating it 'Neutral' or 'Equal Weight,' suggesting a lack of strong conviction for further upside.
NVST Technical Analysis
The stock is in a sustained uptrend, having gained 67.71% over the past year, significantly outperforming the broader market's 30.59% gain. As of the latest close at $26.80, the price is trading at approximately 88% of its 52-week range ($15.49 to $30.42), indicating it is near its recent highs and reflecting strong investor momentum, though also suggesting potential for overextension if the rally stalls. The stock's beta of 0.985 indicates its volatility is nearly in line with the market, which is notable given its substantial price appreciation over the period. Recent momentum shows signs of consolidation following the sharp rally, with the stock up 12.42% over the past three months but only 2.52% over the past month. This deceleration in the 1-month return, especially against a market (SPY) gain of 8.7% over the same period, results in a negative 1-month relative strength of -6.18, signaling the stock is currently lagging the market's recent surge and may be undergoing a period of digestion after its earlier gains. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $30.42 and support at the 52-week low of $15.49. A decisive breakout above $30.42 would signal a resumption of the powerful uptrend, while a breakdown below the recent consolidation range around $25-$27 could indicate a deeper pullback. The stock's maximum drawdown of -19.83% over the provided period highlights its capacity for volatility, which investors must consider for risk management despite its market-aligned beta.
Beta
—
—
Max Drawdown
-19.9%
Largest decline past year
52-Week Range
$16-$30
Price range past year
Annual Return
+36.4%
Cumulative gain past year
| Period | NVST Return | S&P 500 |
|---|---|---|
| 1m | -9.1% | +9.1% |
| 3m | -16.7% | +6.8% |
| 6m | +24.6% | +9.9% |
| 1y | +36.4% | +30.5% |
| ytd | +11.8% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NVST Fundamental Analysis
Revenue growth has accelerated markedly, with Q4 2025 revenue of $750.6 million representing a robust 14.96% year-over-year increase. This growth is being driven primarily by the higher-margin Specialty Products and Technologies segment, which generated $1.21 billion in the period compared to $679.3 million from Equipment and Consumables. The sequential trend from Q1 to Q4 2025 shows revenue climbing from $616.9M to $750.6M, indicating positive momentum throughout the fiscal year. Profitability has improved dramatically, transitioning from a net loss of -$303 million in Q3 2025 to a net income of $32.9 million in Q4 2025. The company maintains a healthy gross margin of 55.04% as of the latest quarter, which is consistent with its historical range and supports the business model. The operating margin for Q4 2025 was 10.10%, a significant recovery from the -182.17% operating margin reported in Q2 2024, which was impacted by a large impairment charge. The balance sheet is solid, with a strong current ratio of 2.38 and a manageable debt-to-equity ratio of 0.55. The company is generating substantial cash, with free cash flow over the trailing twelve months of $230.4 million, providing ample internal funding for growth and share repurchases. Return on equity, however, remains modest at 1.51%, reflecting the company's recent journey back to profitability and the significant equity base.
Quarterly Revenue
$750600000.0B
2025-12
Revenue YoY Growth
+0.14%
YoY Comparison
Gross Margin
+0.55%
Latest Quarter
Free Cash Flow
$230400000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NVST Overvalued?
Given the company's positive net income of $32.9 million in the latest quarter, the primary valuation metric is the P/E ratio. The trailing P/E is elevated at 77.6x, while the forward P/E based on analyst EPS estimates is a much more reasonable 17.2x. This substantial gap implies the market is pricing in a significant recovery and normalization of earnings, with analysts projecting EPS to surge from $0.20 in Q4 2025 to an estimated annual average of $1.89. Compared to sector averages, the stock's forward P/E of 17.2x appears reasonable for a healthcare equipment company, though direct industry average data is not provided in the valuation set for comparison. The price-to-sales ratio of 1.34x and EV/Sales of 1.77x suggest the market is valuing the company at a moderate multiple of its revenue base, which could be attractive if the margin expansion story continues as projected. Historically, the stock's own valuation has compressed significantly from crisis levels; for instance, its trailing P/E in Q4 2024 was 693x due to minimal earnings, which has now normalized. The current forward P/E of 17.2x sits well below the extreme historical highs and suggests the market has priced in the earnings recovery, leaving less room for multiple expansion unless growth accelerates further.
PE
77.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -28x~693x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: NVST's primary financial risk is its valuation dependency on continued high growth and perfect earnings execution. The forward P/E of 17.2x, while reasonable, requires EPS to surge from $0.20 to an estimated $1.89. A slowdown in the 14.96% YoY revenue growth or a failure to maintain the recovered 10.10% operating margin would directly threaten this earnings trajectory and likely trigger multiple compression. While the balance sheet is solid with a debt-to-equity of 0.55 and strong free cash flow, the modest ROE of 1.51% indicates the company is still in the early stages of translating its equity base into substantial profits.
Market & Competitive Risks: The stock trades at 88% of its 52-week high after a 67.71% annual rally, indicating it is priced for perfection and vulnerable to a pullback if momentum stalls, as suggested by its recent negative 1-month relative strength of -6.18. As a dental products company, it faces competitive pressures in both implant systems and orthodontics, and its revenue is concentrated in North America. While its beta of 0.985 suggests market-aligned volatility, its 19.83% maximum drawdown shows it can experience sharper declines than the broader market during risk-off periods.
Worst-Case Scenario: The worst-case scenario involves a combination of a growth slowdown and a broader market sell-off compressing valuation multiples. If revenue growth decelerates below 10% and operating margins contract, analyst EPS estimates could be cut, rendering the forward P/E unjustified. A re-rating to a lower multiple on reduced earnings could drive the stock back toward its 52-week low of $15.49. From the current price of $26.80, this represents a realistic downside of approximately -42%. A more immediate bear case would be a breakdown from the recent consolidation, triggering stop-losses and accelerating a decline toward the $22-$24 support zone, representing a -10% to -18% loss.
FAQ
The key risks are, in order of severity: 1) Execution/Valuation Risk: The stock's forward P/E of 17.2x depends on hitting EPS of $1.89; a growth slowdown or margin miss would trigger multiple compression. 2) Technical/ Momentum Risk: After a 67.71% annual gain, the stock is showing signs of exhaustion with negative 1-month relative strength (-6.18), risking a sharp pullback. 3) Competitive/Market Risk: As a dental products company, it operates in competitive segments and is sensitive to healthcare spending. 4) Coverage/Liquidity Risk: With only 4 analysts, sentiment shifts can cause disproportionate price moves.
Our 12-month forecast outlines three scenarios. The Base Case (60% probability) sees the stock trading between $27 and $30, as it meets EPS estimates of $1.89 and consolidates its gains. The Bull Case (25% probability) projects a breakout above $30.42 to a range of $32-$35, driven by earnings beats and multiple expansion. The Bear Case (15% probability) foresees a correction to $20-$24 on growth deceleration or an earnings miss. The Base Case is most likely, predicated on the assumption that the company's current 14.96% revenue growth rate can be sustained.
NVST is fairly valued based on forward earnings but appears overextended on a technical basis. The trailing P/E of 77.6x is misleading due to past losses; the forward P/E of 17.2x is a more relevant metric and is reasonable for a healthcare equipment company with its growth profile. The price-to-sales ratio of 1.34x also suggests a moderate valuation. However, the stock trades at 88% of its 52-week high after a massive rally, suggesting limited near-term upside. The valuation implies the market expects the company to successfully deliver on analyst EPS estimates of $1.89; any shortfall would likely lead to the stock being deemed overvalued.
NVST is a Hold, not a clear-cut buy at current levels. The company's operational turnaround is compelling, with 14.96% revenue growth and a swing to profitability. However, the stock has already rallied 67.71% in the past year, trading near its 52-week high, which prices in much of the recovery. The forward P/E of 17.2x is fair but requires perfect execution to meet the $1.89 EPS target. For new money, it would be a better buy on a pullback to the low-$20s, improving the risk/reward profile. Patient investors may find it suitable for a long-term position, but should be prepared for volatility.
NVST is more suitable for a long-term investment horizon of 2-3 years rather than short-term trading. The company is in the midst of a multi-quarter turnaround, and realizing the full value of its growth strategy and margin recovery will take time. Its market-aligned beta of 0.985 and history of a -19.83% drawdown indicate it is not a low-volatility holding, making it risky for short-term traders. The lack of a dividend also means total return is dependent solely on price appreciation. Investors should be prepared to hold through volatility to allow the fundamental story to play out.